US 2019/0375826 A1Published application

Anti-dengue virus antibodies and applications thereof

AssigneeNational Defense Medical Center

InventorsSzu-Chia LAI, Yu-Yine HUANG, Chang-Chi LIN, Jiunn-Jye WEY, Meng-Hung TSAI

Life of this patent

Estimating the term…

Loading patent…

Abstract

The present invention relates to anti-virus dengue virus antibodies and applications thereof. Specifically, the anti-virus dengue virus antibodies of the present invention are serotype specific and useful for specific detection and differentiation of various dengue virus serotypes in a biological sample. The present invention also provide methods and kits for detecting dengue virus and methods and compositions for use in diagnosis and treatment of dengue virus disease using the anti-virus dengue virus antibodies as described herein.

Claims21

Dependent claims

An isolated antibody or antigen-binding fragment thereof specific for dengue virus, wherein the isolated antibody is selected from the group consisting of:

(i) a first antibody specific for dengue virus serotype 1 (DENV1) comprising
(a) a heavy chain variable region (VH) which comprises a heavy chain complementary determining region (HC CDR1) of SEQ ID NO:
2, a heavy chain complementary determining region 2 (HC CDR2) of SEQ ID NO:
4, and a heavy chain complementary determining region 3 (HC CDR3) of SEQ ID NO:
6;
and
(b) a light chain variable region (VL) which comprises a light chain complementary determining region 1 (LC CDR1) of SEQ ID NO:
9, a light chain complementary determining region (LC CDR2) of SEQ ID NO:
11, and a light chain complementary determining region 3 (LC CDR3) of SEQ ID NO:
13;
(ii) a second antibody specific for dengue virus serotype 2 (DENV2) comprising
(a) a VH which comprises a HC CDR1 of SEQ ID NO:
16, a HC CDR2 of SEQ ID NO:
18, and a HC CDR3 of SEQ ID NO:
20;
and
(b) a VL which comprises a LC CDR1 of SEQ ID NO:
23, a LC CDR2 of SEQ ID NO:
25, and a LC CDR3 of SEQ ID NO:
27;
(iii) a third antibody specific for dengue virus serotype 3 (DENV3) comprising
(a) a VH which comprises a HC CDR1 of SEQ ID NO:
30, a HC CDR2 of SEQ ID NO:
32, and a HC CDR3 of SEQ ID NO:
34;
and
(b) a VL which comprises a LC CDR1 of SEQ ID NO:
37, a LC CDR2 of SEQ ID NO:
39, and a LC CDR3 of SEQ ID NO:
41;
(iv) a fourth antibody specific for dengue virus serotype 4 (DENV4) comprising
(a) a VH which comprises a HC CDR1 of SEQ ID NO:
44, a HC CDR2 of SEQ ID NO:
46, and a HC CDR3 of SEQ ID NO:
48;
and
(b) a VL which comprises a LC CDR1 of SEQ ID NO:
51, a LC CDR2 of SEQ ID NO:
53, and a LC CDR3 of SEQ ID NO:
55;
and
(v) a fifth antibody cross-reactive to DENV1, DENV2, DENV3 and DENV4 comprising
(a) a VH which comprises a HC CDR1 of SEQ ID NO:
58, a HC CDR2 of SEQ ID NO:
60, and a HC CDR3 of SEQ ID NO:
62;
and
(b) a VL which comprises a LC CDR1 of SEQ ID NO:
65, a LC CDR2 of SEQ ID NO:
67, and a LC CDR3 of SEQ ID NO:
69;
and
(vi) any combination of (i) to (v).

50 more elements

A method for detecting dengue virus in a sample suspected of containing said dengue virus, comprising contacting the sample with an isolated antibody or antigen-binding fragment thereof specific for dengue virus, and assaying binding of the antibody with said sample, wherein the isolated antibody is selected from the group consisting of:

(i) a first antibody specific for dengue virus serotype 1 (DENV1) that comprises a VH comprising a HC CDR1 of SEQ ID NO:
2, a HC CDR2 of SEQ ID NO:
4, and a HC CDR3 of SEQ ID NO:
6;
and a VL comprising a LC CDR1 of SEQ ID NO:
9, a LC CDR2 of SEQ ID NO:
11, and a LC CDR3 of SEQ ID NO:
13;
(ii) a second antibody specific for dengue virus serotype 2 (DENV2) that comprises a VH comprising a HC CDR1 of SEQ ID NO:
16, a HC CDR2 of SEQ ID NO:
18, and a HC CDR3 of SEQ ID NO:
20;
and a VL comprising a LC CDR1 of SEQ ID NO:
23, a LC CDR2 of SEQ ID NO:
25, and a LC CDR3 of SEQ ID NO:
27;
(iii) a third antibody specific for dengue virus serotype 3 (DENV3) that comprises a VH comprising a HC CDR1 of SEQ ID NO:
30, a HC CDR2 of SEQ ID NO:
32, and a HC CDR3 of SEQ ID NO:
34;
and a VL comprising a LC CDR1 of SEQ ID NO:
37, a LC CDR2 of SEQ ID NO:
39, and a LC CDR3 of SEQ ID NO:
41;
(iv) a forth antibody specific for dengue virus serotype 4 (DENV4) that comprises a VH comprising a HC CDR1 of SEQ ID NO:
44, a HC CDR2 of SEQ ID NO:
46, and a HC CDR3 of SEQ ID NO:
48;
and a VL comprising a LC CDR1 of SEQ ID NO:
51, a LC CDR2 of SEQ ID NO:
53, and a LC CDR3 of SEQ ID NO:
55;
and
(v) any combination of (i) to (iv).

31 more elements

A kit for detecting the presence of dengue virus in a sample, wherein the kit comprises one or more antibodies specific to dengue virus, selected from the group consisting of:

(i) a first antibody specific for dengue virus serotype 1 (DENV1) that comprises a VH comprising a HC CDR1 of SEQ ID NO:
2, a HC CDR2 of SEQ ID NO:
4, and a HC CDR3 of SEQ ID NO:
6;
and a VL comprising a LC CDR1 of SEQ ID NO:
9, a LC CDR2 of SEQ ID NO:
11, and a LC CDR3 of SEQ ID NO:
13;
(ii) a second antibody specific for dengue virus serotype 2 (DENV2) that comprises a VH comprising a HC CDR1 of SEQ ID NO:
16, a HC CDR2 of SEQ ID NO:
18, and a HC CDR3 of SEQ ID NO:
20;
and a VL comprising a LC CDR1 of SEQ ID NO:
23, a LC CDR2 of SEQ ID NO:
25, and a LC CDR3 of SEQ ID NO:
27;
(iii) a third antibody specific for dengue virus serotype 3 (DENV3) that comprises a VH comprising a HC CDR1 of SEQ ID NO:
30, a HC CDR2 of SEQ ID NO:
32, and a HC CDR3 of SEQ ID NO:
34;
and a VL comprising a LC CDR1 of SEQ ID NO:
37, a LC CDR2 of SEQ ID NO:
39, and a LC CDR3 of SEQ ID NO:
41;
(iv) a forth antibody specific for dengue virus serotype 4 (DENV4) that comprises a VH comprising a HC CDR1 of SEQ ID NO:
44, a HC CDR2 of SEQ ID NO:
46, and a HC CDR3 of SEQ ID NO:
48;
and a VL comprising a LC CDR1 of SEQ ID NO:
51, a LC CDR2 of SEQ ID NO:
53, and a LC CDR3 of SEQ ID NO:
55;
(v) any combination of (i) to (iv);
and
(vi) an optional partner antibody.

32 more elements

Dependencies are inferred from the claim text.

Facts

Application: 16/006,000Filed 12 Jun 2018
Published: 12 Dec 2019
Term ends: Not estimatedThe source records don’t support an estimate.

Classification12 codes

C07K 16/116
RNA viruses: togaviridae ; Matonaviridae ; Flaviviridae
G01N 33/56983
For microorganisms, e.g. protozoa, bacteria, viruses: viruses
G01N 33/58
Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing:…
C07K 2317/31
Characterized by aspects of specificity or valency: multispecific

Family

US 10,526,398 B2Related patent
US 2019/0375826 A1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

Building an agent or pulling many patents? Use the API or MCP server instead of scraping pages. Get an API key